Date	Stock	Type	Shares	Price	Value	Holding	Reported
Dec 6, 2018	OCULOcular Therapeutix	↑ Buy	17,400	$5.76	$100K	Direct	Dec 10, 2018 (4d)
Dec 6, 2017	OCULOcular Therapeutix	↑ Buy	24,700	$3.93	$97K	Direct	Dec 8, 2017 (2d)
Jan 9, 2017	ARIAAriad Pharmaceuticals	↓ Sell	32,000	$23.78	$761K	Direct	Jan 10, 2017 (1d)
Oct 3, 2016	ARIAAriad Pharmaceuticals	↓ Sell	47,384	$13.46	$638K	Direct	Oct 5, 2016 (2d)
Mar 21, 2016	ARIAAriad Pharmaceuticals	↓ Sell	4,000	$6.47	$26K	Direct	Mar 22, 2016 (1d)
Mar 3, 2016	ARIAAriad Pharmaceuticals	↓ Sell	9,625	$6.11	$59K	Direct	Mar 3, 2016 (0d)
Feb 1, 2016	ARIAAriad Pharmaceuticals	↓ Sell	14,667	$4.81	$71K	Direct	Feb 3, 2016 (2d)
Sep 28, 2015	ARIAAriad Pharmaceuticals	↓ Sell	5,000	$6.46	$32K	Direct	Sep 28, 2015 (0d)
Jul 16, 2015	ARIAAriad Pharmaceuticals	↓ Sell	4,000	$8.54	$34K	Direct	Jul 16, 2015 (0d)
Mar 23, 2015	ARIAAriad Pharmaceuticals	↓ Sell10b5-1	7,000	$8.72	$61K	Direct	Mar 23, 2015 (0d)
Mar 16, 2015	ARIAAriad Pharmaceuticals	↓ Sell	34,425	$8.62	$297K	Direct	Mar 18, 2015 (2d)
Feb 2, 2015	ARIAAriad Pharmaceuticals	↓ Sell10b5-1	14,667	$6.33	$93K	Direct	Feb 4, 2015 (2d)
Sep 2, 2014	ARIAAriad Pharmaceuticals	↓ Sell	56,650	$6.22	$352K	Direct	Sep 4, 2014 (2d)
Apr 2, 2014	ARIAAriad Pharmaceuticals	↓ Sell10b5-1	2,400	$8.22	$20K	Direct	Apr 3, 2014 (1d)
Mar 21, 2014	ARIAAriad Pharmaceuticals	↓ Sell10b5-1	2,400	$7.89	$19K	Direct	Mar 21, 2014 (0d)
Dec 19, 2013	ARIAAriad Pharmaceuticals	↓ Sell10b5-1	3,600	$5.15	$19K	Direct	Dec 20, 2013 (1d)
Jul 18, 2013	ARIAAriad Pharmaceuticals	↓ Sell	6,400	$19.79	$127K	Direct	Jul 18, 2013 (0d)
Apr 2, 2013	ARIAAriad Pharmaceuticals	↓ Sell	2,400	$18.05	$43K	Direct	Apr 3, 2013 (1d)
Mar 25, 2013	ARIAAriad Pharmaceuticals	↓ Sell	12,933	$18.87	$244K	Direct	Mar 26, 2013 (1d)
Mar 22, 2013	ARIAAriad Pharmaceuticals	↓ Sell	2,400	$19.46	$47K	Direct	Mar 22, 2013 (0d)
Oct 1, 2012	ARIAAriad Pharmaceuticals	↓ Sell	7,500	$25.00	$188K	Direct	Oct 2, 2012 (1d)
Sep 19, 2012	ARIAAriad Pharmaceuticals	↓ Sell	7,500	$24.00	$180K	Direct	Sep 20, 2012 (1d)
Sep 11, 2012	ARIAAriad Pharmaceuticals	↓ Sell	7,500	$23.00	$173K	Direct	Sep 12, 2012 (1d)
Jul 30, 2012	ARIAAriad Pharmaceuticals	↓ Sell	7,500	$19.00	$143K	Direct	Aug 1, 2012 (2d)
Jun 22, 2012	ARIAAriad Pharmaceuticals	↓ Sell	7,500	$17.50	$131K	Direct	Jun 25, 2012 (3d)
Oct 26, 2010	ARIAAriad Pharmaceuticals	↑ Buy	3,000	$3.70	$11K	Direct	Oct 27, 2010 (1d)

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other OCUL insiders

Open-market trades in the last 12 months

Todd Anderman

Chief Scientific Officer

5 sales

Oct 2, 2026

Peter Kaiser

Chief Development Officer

5 sales

Oct 2, 2026

Donald Notman

Chief Operating Officer

3 sales

Aug 31, 2026

Sanjay Nayak

Chief Strategy Officer

Richard L Md Lindstrom

Chief Medical Officer

2 sales

Feb 20, 2026

About Daniel M Bollag's insider trades

Daniel M Bollag is Sr. VP Reg. Affairs & Quality at Ocular Therapeutix (OCUL). Since Oct 26, 2010, Daniel has reported 3 open-market purchases worth $208K and 23 sales worth $3.8M on SEC Form 4. There have been no open-market trades in the last 12 months.

5 sales (6% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.

Their filings also include option exercises (32 filings), grants and awards (15 filings), shares withheld for taxes (9 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OCUL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.